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Abstract: Baclofen, an agonist at the B subunit of gaba-aminobutyric acid receptor, possesses 
pharmacologic properties that may confer utility for the treatment of alcohol dependence. 
Research suggests that not only can it be useful in promoting maintenance of alcohol abstinence 
but also it may play a key role in decreasing alcohol cravings and anxiety often associated with 
alcohol dependence. To assess the benefit of baclofen for alcohol dependence, a review of the 
literature was conducted to identify published data investigating this off-label treatment. Four 
randomized controlled trials to date have been published and were included in this review. 
Although primary outcomes differ between studies, patients randomized to baclofen experience 
higher rates of abstinence from alcohol than those taking placebo in two of the trials. Secondary 
analyses indicate that baclofen is safe in patients with alcohol dependence, including those with 
moderate to severe liver cirrhosis, and may provide beneficial anxiolytic effects. Despite some 
positive data, the largest available randomized controlled trial failed to find any differences 
between baclofen and placebo. In all studies, individuals with severe medical comorbidities, 
seizure disorders, and psychiatric disorders were excluded from trials, which may limit external 
validity. In summary, there may be beneficial effects from using baclofen for the treatment of 
alcohol dependence; however, limited conclusions can be drawn from the small number of 
studies currently available for review. Larger well-designed trials are needed to further define 
baclofen’s role for the treatment of alcohol dependence.
Keywords: baclofen, alcohol, abstinence, relapse, craving, dependence
Introduction
Alcohol misuse is one of the world’s leading health risks. Alcohol abuse and depen-
dence are associated with more than 60 disease types and injuries that contribute to 
approximately 2.5 million deaths annually.1 An estimated 4.5% of the global burden 
of disease and injury is attributed to alcohol. Alcohol is also associated with exorbitant 
social costs, such as those related to violence, child neglect/abuse, and absenteeism in 
the workplace.1 Therapeutic approaches, including pharmacotherapy, play a pivotal 
role in treating patients with alcohol use disorders but are commonly underutilized.2 
Since the 1951 approval of disulfiram by the Food and Drug Administration (FDA), 
three additional treatments have been approved for the treatment of alcohol dependence: 
acamprosate, oral naltrexone, and intramuscular naltrexone.3
Despite mixed data from well-designed trials of disulfiram, acamprosate, or 
 naltrexone, two recent Cochrane reviews concluded that acamprosate and nal-
trexone appear to be safe and effective in patients with alcohol dependence, with 
moderate effect sizes.4–8 However, due to various barriers to the use of acamprosate, 
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 naltrexone, or disulfiram, some patients are unable to take 
these FDA-approved agents. Acamprosate is contraindicated 
in patients with severe renal impairment (ie, estimated crea-
tinine clearance [CrCl] ,30 mL/min), and gastrointestinal 
adverse events may prevent use or limit dose maximization. 
 Naltrexone is contraindicated in patients with acute hepati-
tis or hepatic failure and may not be used in patients with 
concomitant opioid utilization. Disulfiram must be used 
with caution in multiple disease states, such as diabetes 
mellitus, hypothyroidism, and seizures; patients must also be 
warned not to consume “hidden” alcohol, such as tonics and 
mouthwashes, in order to avoid unintended toxic effects of 
the medication. Nonadherence with oral naltrexone remains 
a barrier to effective treatment for a large portion of patients, 
so intramuscular naltrexone has been developed for once-
monthly administration and has additional advantages of 
steady therapeutic drug concentration and decreased peak 
and trough effects.9
The off-label use of multiple medications, including 
baclofen, has been investigated for maintenance of abstinence 
from alcohol. Baclofen was originally approved by the FDA 
in 1977 for use in spasticity associated with neurologic con-
ditions, such as multiple sclerosis and spinal cord lesions.10 
Baclofen’s pharmacologic properties have led to investiga-
tion of its benefit for the treatment of alcohol dependence.
Baclofen: pharmacokinetics  
and pharmacodynamics
Baclofen is an agonist at the B subunit of gaba-aminobutyric 
acid receptor (GABA
B
). GABA
B
 receptors are metabotropic 
and differ from the ionotropic GABA
A
 and GABA
C
 receptors. 
GABA
B
 receptors are highly expressed in the limbic system, 
suggesting a major role in regulating emotional behavior. 
GABA neurotransmission is also known to be an important 
factor in the control of anxiety. Following these lines of evi-
dence, activation of GABA
B
 receptors might reduce anxiety.11 
Noting that anxiety is a common symptom in patients being 
treated for alcohol withdrawal and alcohol dependence, acti-
vating GABA
B
 receptors might be useful in the treatment of 
alcohol withdrawal and dependence.
Mesolimbic dopamine neurons, found in the same areas of 
the brain as GABA
B
 receptors, are thought to be involved in 
the mediation of alcohol intake and reinforcement. Activation 
of GABA
B
 receptors by baclofen may result in local inhibition 
of surrounding dopamine neurons. Through this mechanism, 
alcohol-stimulated dopamine release would be reduced, 
thereby decreasing positive reinforcement from alcohol 
consumption and aiding in abstinence from alcohol.12
Despite high individual variation in pharmacokinetics, 
baclofen is rapidly and extensively absorbed from the gas-
trointestinal tract following oral administration, though there 
is some suggestion that absorption is inversely related to 
dose.13,14 Peak plasma concentrations are generally observed 
2–3 hours after ingestion. Baclofen’s elimination half-life is 
2–6 hours and it is usually dosed three to four times daily.13 
Baclofen is excreted primarily unchanged by the kidneys, 
making it a useful agent in patients with impaired hepatic 
function or a high potential for hepatic cytochrome P450-
mediated drug-drug interactions.
Evidence for baclofen  
in maintenance of alcohol 
dependence: a critical evaluation
Numerous case reports, case series, and open-label trials 
have been published evaluating baclofen for the treatment 
of alcohol dependence; most of the primary outcomes focus 
on abstinence from alcohol (Table 1.) Limited data are avail-
able from well-conducted trials, though numerous trials are 
underway or recently completed with a goal of evaluating 
baclofen for maintenance of abstinence in alcohol-dependent 
patients.15 A search of MedLine (1966–2013) using the terms 
“baclofen,” “alcohol,” “abstinence,” “relapse,” “craving,” and 
“dependence” was conducted to identify English language 
articles. Randomized controlled trials (RCTs) are evaluated 
in the following text and summarized in Table 2.
Addolorato et al16 conducted an RCT evaluating the 
effectiveness and safety of baclofen for maintenance of 
alcohol abstinence specifically in patients with cirrhosis 
of the liver. All subjects had a biopsy-proven diagnosis of 
cirrhosis; their alcohol intake included at least two heavy 
drinking days per week, with an average of at least 21 drinks 
weekly for men and 14 drinks weekly for women. Exclusion 
criteria included the presence of severe cardiac or pulmonary 
disease. Individuals with other addictions (except nicotine), 
pharmacologically treated psychiatric diagnoses, epilepsy, 
a severe medical illness, renal dysfunction, or the use of inter-
feron or corticosteroids within 60 days of enrolment were also 
excluded. Subjects were initially hospitalized for 3–4 days 
to complete a medical evaluation and treatment for alcohol 
 withdrawal syndrome (AWS) with diazepam. After resolution 
of AWS, subjects were eligible for  randomization. Eighty-
four subjects with a median age of 56 years (interquartile 
range 45.5–62 years) were included in this study. The active 
treatment group received baclofen 10 mg orally three times 
daily. Assessments and counseling sessions occurred weekly 
for 4 weeks and then biweekly for the remainder of the 
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Table 2 Description of randomized controlled trials
Source Addolorato et al16 Garbutt et al18 Addolorato et al19
Setting Single inpatient site Outpatients recruited from community Single inpatient site
Subjects
 Number
 Age (y)
 Male gender
 Daily drinks
 Duration of use (y)
 Comorbidities
84
49.0 (range 43.0–61.0)
76%
Not reported
22.0 (range 17.0–27.0)
Cirrhosis (Child-Pugh A, B, or C)
80
47.5 ± 7.6
55%
7.3 ± 3.7 (baclofen group)
23.5 ± 9.9
No medical/psychiatric
39
45.8 ± 10.6
Not reported
14.2 ± 7.9 (all subjects)
12.6 ± 4.8
No medical/psychiatric
Intervention Baclofen 10 mg po tid for 12 weeks Baclofen 10 mg po tid for 12 weeks Baclofen 10 mg po tid for 4 weeks
Primary outcome/ 
results
Percentage of patients maintaining 
abstinence: 71% vs 29% (P = 0.0001)
Cumulative abstinent days:  
62.8 ± 5.4 vs 30.8 ± 5.5 (P = 0.001)
Percentage of heavy drinking days:  
19.3% vs 24.7% (P = 0.73)
Percentage of abstinent days:  
51.7% vs 51.6% (P = 0.61)
Percentage of patients maintaining 
abstinence: 70% vs 21.2% (P , 0.005)
Cumulative abstinent days:  
19.6 ± 2.6 vs 6.3 ± 2.4 (P , 0.005)
Note: Reported as mean + standard deviation unless noted otherwise. 
Abbreviations: po, orally; tid, three times daily; vs, versus; y, years.
12-week study period. The primary outcome was the effect 
of baclofen on total abstinence and cumulative abstinence 
duration. Craving level was assessed using a version of the 
Obsessive Compulsive Drinking Scale.
A greater proportion of subjects maintained abstinence in 
the baclofen group compared with the placebo group (71% 
versus [vs] 29%; odds ratio [OR] 6.3 [95% confidence inter-
val (CI) 2.4–16.1]). There was also a greater mean cumulative 
days abstinent in the treatment group (62.8 days) versus the 
placebo group (30.8 days) (P = 0.001). Survival analysis 
demonstrated a lower rate of 60-day relapse with baclofen 
treatment as compared with placebo (hazard ratio 0.4 [95% CI 
0.2–0.8]). Subjects with Child-Pugh class B and C cirrhosis 
assigned to the baclofen group were more likely to abstain 
from alcohol altogether than those in the placebo group 
(OR 4.5 [95% CI 1.2–17.4] and 8.3 [95% CI 1.7–41.3]), 
 respectively. No significant difference was observed for 
subjects with Child-Pugh class A cirrhosis. Baclofen treat-
ment did result in a statistically significant improvement in 
Obsessive Compulsive Drinking Scale scores, suggesting less 
craving for alcohol in those on baclofen therapy. Laboratory 
values improved among those randomized to baclofen and 
were consistent with decreased alcohol use, reflected by 
decreased transaminases and improved markers of synthetic 
liver function. Baclofen was well tolerated and there were 
no life-threatening adverse events reported with baclofen use 
(headache, n = 4; vertigo, n = 2; tiredness, n = 1; sleepiness, 
n = 1) or with its discontinuation at the end of the treatment 
phase.
A post hoc analysis from the same study evaluated only 
subjects with a secondary diagnosis of hepatitis C virus 
(HCV) infection.17 As with the entire cohort, subjects with 
HCV demonstrated a greater likelihood of total alcohol 
 abstinence when taking baclofen (83.3%) versus placebo 
(25%); P = 0.01. However, these results should be interpreted 
with caution, given the limitations of post hoc analyses, with 
additional well-conducted studies needed to confirm the 
safety and efficacy in patients with HCV infection.
Based on the data from Addolorato et al,16 baclofen 
appears to be a well-tolerated and effective medication for 
the promotion of alcohol abstinence in patients with cirrhosis. 
It is important to note limitations of the study, however, 
including limited ability to generalize the findings to other 
patient populations (limited external validity), given the 
narrow inclusion and exclusion criteria. In addition to prob-
lems with external validity, the study exhibits challenges 
related to statistical inference and missing data. For instance, 
although various laboratory parameters were reported as 
statistically different from group to group, it is difficult to 
ascertain clinical significance without information about the 
actual laboratory values in the two groups. Additionally, it is 
unclear whether bias was introduced due to the use or choice 
of benzodiazepine used to treat initial symptoms associated 
with AWS. Although a similar number of patients received 
treatment with diazepam (13 subjects in the baclofen group 
received diazepam vs eleven in the placebo group), the mean 
dosage received was not available. Given that diazepam has 
a long elimination half-life, which may be additionally pro-
longed in liver disease, its use may have impacted craving for 
alcohol and symptoms of anxiety and irritability traditionally 
associated with withdrawal.
Garbutt et al18 conducted a double-blind RCT assess-
ing the efficacy and safety of a total daily dose of 30 mg of 
baclofen for alcohol dependence. The primary outcomes of 
the study were number of heavy drinking days and propor-
tion of abstinence between groups. Other outcomes included 
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percentage abstinent days, time to usage, craving, anxiety, 
depression, and safety information. Individuals with a diag-
nosis of alcohol dependence and at least two heavy drinking 
days weekly during the 4 weeks prior to enrolment were 
eligible for participation. Those with significant medical 
comorbidities, including seizure disorder, psychiatric diag-
noses, or abnormal hepatic or renal laboratory values, were 
excluded. Concomitant use of insulin, oral antihypergly-
cemics, anticonvulsants, and psychotropics (except stable 
doses of antidepressants) was not permitted. Subjects were 
evaluated at baseline and weekly for 4 weeks and then twice 
monthly for the remainder of the 12-week study period. They 
also received eight psychosocial sessions during the study 
time frame. Eighty subjects were included; randomization 
was stratified by sex. Of the 44 men, 22 received baclofen 
and 22 received placebo. A total of 36 women were included, 
and 18 were randomized to baclofen therapy.
In the baclofen group, 25.5% ± 23.6% of days over the 
12-week period were described as heavy drinking days; this 
was statistically indistinguishable from the 25.9% ± 23.6% of 
days described as heavy drinking days in the placebo group 
(P = 0.56). There were no differences between groups in 
terms of weekly heavy drinking days, percentage abstinent 
days, or for the secondary outcomes of craving, depression, 
or anxiety. Though the study failed to demonstrate benefit 
from the drug, baclofen was well tolerated with no signifi-
cant reported adverse events. Drowsiness (placebo, n = 4; 
baclofen, n = 11) and headache (placebo, n = 4; baclofen, 
n = 1) were the most commonly reported events and did not 
differ between groups. A limitation in this study relates to 
the stringent exclusion criteria, which may have excluded 
subjects who could have derived benefit and also limits 
generalizability (ie, a threat to external validity). Moreover, 
subjects in this study may have been less severely dependent 
on alcohol than in the Addolorato study, and baclofen may 
have more impact on more dependent individuals.
The two aforementioned trials were conducted in response 
to open-label data, and a preliminary 30-day double-blind 
RCT conducted by Addolorato et al19 in 2002 at the same 
facility from which the 2007 data were obtained. In this trial, 
39 subjects with a diagnosis of alcohol dependence were 
randomized to receive placebo or baclofen titrated to a total 
daily dose of 30 mg by day 4 of the study. To be included in 
the study, subjects were required to have consumed alcohol 
within 24 hours of enrolment, and they were required to have 
a family member available to participate in follow-up visits 
and to ensure adherence. Individuals with severe kidney, 
liver, or heart disease were excluded, as were those with 
psychopathologic illnesses, addiction to other substances 
(except nicotine), and seizure disorders or those using anti-
epileptic medications. After randomization, subjects could 
receive emergent diazepam for symptoms associated with 
AWS, though none required this intervention. Subjects were 
evaluated weekly for outcomes related to abstinence using 
patient self-report and alcohol concentration. Cravings, 
biologic markers of alcohol abuse, anxiety, depression, 
and adverse events during the trial were also assessed on a 
weekly basis.
A greater percentage of subjects in the baclofen group 
(70%) achieved and maintained abstinence versus the placebo 
group (21.1%, P , 0.005). The cumulative days abstinent 
(±standard error of the mean) over the 4-week period was 
also greater in the baclofen group, 19.6 ± 2.6 days and 
6.3 ± 2.4 days (P , 0.005). Mean number of daily drinks 
decreased over the course of 2 weeks from 18 to less than 
0.5 in the baclofen group, compared with a decrease from ten 
to four in the placebo group. Secondary outcomes of cravings 
and anxiety were significantly reduced in those treated with 
baclofen as compared with placebo, but scores for depressive 
symptoms did not differ between the two groups. No statisti-
cal analysis was conducted on biologic markers of hepatic 
function; however, both groups had reductions of gamma-
glutamyl transpeptidase, aspartate aminotransferase, and 
alanine transaminase by approximately 50% from baseline. 
Baclofen was well tolerated, with no discontinuations for 
adverse events. The most commonly reported side effect in 
the treatment group was sleepiness (n = 2). The duration of 
the trial was short, leading to the evaluation of baclofen in 
longer trials with larger sample sizes.
Information regarding a fourth double-blind RCT, which 
planned to evaluate the effect of baclofen on the maintenance 
of abstinence, has been described.10 However, data are avail-
able only from a post hoc analysis in a separate publication, 
due to protocol violations and recruitment issues.20 The 
International Baclofen Intervention Study (IBIS) attempted 
to recruit subjects from four European countries. Baclofen 
60 mg daily, baclofen 30 mg daily, and placebo groups 
were compared for the primary outcomes of heavy drinking 
days, abstinence days, and alcohol craving. Assessments 
were made at weekly intervals for the first 4 weeks and 
then decreased to every other week for the remainder of 
the 12-week trial. There was also a final follow-up visit at 
week 16, 4 weeks after the last dose of baclofen or placebo. At 
enrolment, patients were assessed and treated for AWS with 
diazepam when necessary. Those requiring AWS treatment 
for greater than 10 days were excluded. Brief psychological 
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intervention was provided and medication adherence was 
assessed at each follow-up assessment.
Due to protocol violations and missing data, authors 
excluded 51 subjects from Australian and Austrian study 
sites, and a third site in the UK did not enrol any patients. 
Primary analysis of the IBIS study data is commented upon 
in a second publication20 and reported that no significant 
differences were found for primary outcomes but noted that 
due to exclusions the study failed to meet power.
In this second publication is also a post hoc analysis of 
the 42 Italian subjects meeting the inclusion and exclusion 
criteria of the IBIS study. Reported as incidence rate ratios 
when compared with placebo, baclofen 30 mg was reported 
to have a 53% reduction of daily drinks and baclofen 60 mg 
daily a 68% reduction of daily drinks (P , 0.001). The 
authors concluded that there was an association between 
increasing dose and increasing effect (P = 0.0214). This 
study utilized doses higher than those previously studied for 
this indication; however, all treatment groups continued to 
have minimal adverse events, with headache and sleepiness 
those most commonly reported. Due to the small number of 
subjects and the post hoc nature, it is difficult to draw firm 
conclusions regarding the benefit of 60 mg compared with 
30 mg of baclofen for this indication. Further well-conducted 
studies are needed to confirm whether higher doses of 
baclofen may confirm greater efficacy.
Is baclofen safe for maintenance  
of alcohol dependence?
Baclofen has been used safely for decades as an antispastic-
ity medication. Only recently has the understanding of the 
pathophysiology of alcohol dependence evolved, leading 
to the evaluation of baclofen’s role for the maintenance 
of alcohol dependence. Although data are mixed regard-
ing baclofen’s efficacy in alcohol dependence, data are 
consistent in terms of safety. The most commonly reported 
adverse events include headache, drowsiness, nausea, and 
vertigo.11,18–20 In addition to central nervous system effects, 
nausea may occur in up to 12% of patients but can be mini-
mized by gradual titration to a target dose or taking baclofen 
with food.21 No difference in adverse events between the 
30 mg and 60 mg daily dosing has been identified.20 Literature 
supporting higher doses of baclofen, mostly case reports and 
series, has reported the safe use of doses up to 275 mg daily.22 
However, there are very limited safety data utilizing high-
dose baclofen in alcohol-dependent patients, and significant 
adverse events have been reported, including overdose and 
seizures.21–23
Evidence also supports baclofen as a safe maintenance 
treatment for alcohol dependence, even when patients con-
tinue to consume alcohol or resume drinking alcohol. Evans 
and Bisaga24 studied 18 heavy social drinkers who consumed 
intoxicating levels of alcohol and demonstrated no adverse 
effects from the combination of alcohol and baclofen. Rare 
but serious adverse effects associated with baclofen in other 
uses, including encephalopathy, seizure, and hyperammone-
mia, have not been identified in clinical trials investigating 
its use for alcohol dependence.11,18–20 No negative sequelae 
have been reported with baclofen discontinuation in alcohol 
dependence studies, though seizures and other neuropsychiat-
ric symptoms have been reported after abrupt discontinuation 
of oral baclofen when used for other indications.21 The lack 
of noted adverse events may be a result of small sample sizes 
and low doses of baclofen utilized in available trials, and 
clinicians should remain mindful of possible rare adverse 
events associated with baclofen. However, with available 
data suggesting safety, further investigation of baclofen’s 
role in the treatment of alcohol dependence is warranted.
Discussion
The evidence supporting the safe and effective use of 
baclofen for maintenance treatment of alcohol dependence 
is growing, as evidenced by the number of ongoing or 
recently completed trials. From the studies reviewed here, 
it appears that baclofen may prolong the time to first drink, 
reduce overall drinking days, and facilitate maintenance of 
abstinence in select populations. Baclofen appears to be well 
tolerated at the doses that have been evaluated. The available 
evidence suggests a potentially unique impact of baclofen 
for the treatment of alcohol dependence, given that it has 
been safely used in patients with comorbid cirrhosis of the 
liver, a disease that is not uncommon in alcohol-dependent 
patients. However, the role of baclofen in patients with other 
medical and psychiatric comorbidities remains unclear. 
With the exception of stable antidepressant use, those with 
a treated comorbid psychiatric illness were excluded from 
RCTs. As the efficacy of baclofen has not been conclusively 
confirmed for the maintenance of alcohol abstinence, exclud-
ing subjects taking other psychotropic medications may avoid 
confounding from other psychotropic agents that may have 
beneficial effects on alcohol intake. However, baclofen may 
provide clinical benefit in those with underlying anxiety, 
and expanding future inclusion criteria in clinical trials 
would be important to test this hypothesis. Addolorato et al19 
found improvements in anxiety but not depression scores 
in patients treated with baclofen. The anxiolytic effects of 
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baclofen have also been shown to be greater than placebo in 
alcoholic patients, producing similar results to both low-dose 
amitriptyline and diazepam, though in that particular study 
abstinence from alcohol was not measured or reported.25 
One case report describes a patient with schizophrenia and 
alcohol dependence who experienced decreased alcohol 
intake and cravings when he was treated with baclofen.26 
Additionally, Dore et al22 reported a case series of baclofen 
use in dually diagnosed individuals (n = 13). When doses 
ranging from 30 mg to 275 mg of baclofen were used daily, 
eight (61.5%) subjects experienced a significant abstinence 
period or reduction in drinking quantity. Four subjects also 
reported beneficial anxiolytic effects. Unfortunately, two 
subjects overdosed with baclofen, and seven patients experi-
enced mild to moderate adverse events, including drowsiness, 
nocturnal enuresis, forgetfulness, and dizziness. Additional 
data supporting the efficacy and safety of baclofen in dually 
diagnosed patients are warranted and necessary before it can 
be firmly recommended over other potential options.
RCTs of baclofen for the maintenance of alcohol 
abstinence also excluded patients with documented sei-
zure disorders. However, it is unclear whether individuals 
with alcohol-related seizures were also excluded. It has 
been estimated that at least 15% of patients with alcohol 
dependence have a documented seizure history. Alcohol 
itself is a significant risk factor for the development of 
status epilepticus.27 Though prospective trials of baclofen 
for alcohol dependence have not demonstrated increased 
seizure risk, the package insert and other trials report a risk 
of baclofen-related seizures at doses greater than 200 mg per 
day.13,28 Albeit a rare event, the association of seizures with 
baclofen withdrawal and overdose should bring awareness 
for the potential for seizure-related complications. This fact 
was highlighted in one case report describing a patient with 
no seizure history who developed two seizures while being 
treated with baclofen 240 mg daily for the maintenance of 
alcohol abstinence.23
An additional population excluded in the trials discussed 
was those with renal dysfunction. Renal impairment can 
lead to the accumulation of baclofen, resulting in increased 
adverse events. Currently, there are no manufacturer recom-
mendations for renal dose adjustments for baclofen. There are 
also limited data on baclofen toxicity in patients with varying 
degrees of renal impairment. El-Husseini et al14 proposed that 
baclofen not be given to those with CrCl ,30 mL/min and 
be initiated and titrated slowly when CrCl is 30–50 mL/min. 
It has also been suggested to use caution in patients with 
subclinical or mild renal impairment, as serum concentration 
of stable baclofen doses has been observed to increase over 
time.29
Given the limited external validity and methodological 
limitations of current literature, clinicians should be aware of 
other medications studied off label for maintenance of alcohol 
abstinence. Although an extensive review of such agents is 
beyond the scope of this article, medications that have been 
studied include antiepileptic agents. Topiramate, gabapentin, 
and pregabalin have also been studied in RCTs and have 
demonstrated benefits for decreasing the percentage of heavy 
drinking days, percentage of days abstinent from alcohol, and 
number of drinks per day.2,30,31 These medications have the 
advantages of increasing the seizure threshold and having spe-
cific FDA-approved renal dosing recommendations for patients 
with renal impairment. Gabapentin and pregabalin have also 
been shown to have beneficial effects on anxiety. Limitations 
to the use of these agents include adverse cognitive effects that 
may limit topiramate titration to an optimal dose, and the rare 
occurrence of euphoria associated with pregabalin.
Other medications, such as quetiapine, a second-generation 
antipsychotic, have been specifically studied in dual-diagnosed 
patients (psychiatric disorder and alcohol dependence) and 
may confer decreased alcohol consumption and cravings.32 
Quetiapine has also been studied for bipolar disorder, 
depression, generalized anxiety disorder, and schizophrenia. 
 Available data are mixed, but quetiapine may be a consider-
ation in alcohol-dependent patients with a comorbid psychiat-
ric diagnosis, with its effect, in part, from promoting stability 
of the co-occurring psychiatric diagnosis.32–34
Conclusion
Currently published literature involving baclofen for the 
maintenance of alcohol abstinence is limited and difficult 
to apply to many patient populations. However, trials 
are currently ongoing, and the role of baclofen should become 
clearer as results are made known. Clinicians should be aware 
of both the risks and benefits associated with baclofen and its 
selection over other second-line agents. Selection of an agent 
for this indication should be based on patient characteristics, 
including organ function and comorbid diseases, specifically 
psychiatric illnesses and seizure disorders of any type.
Although the literature is not sufficient to recommend 
baclofen as a first-line agent for the treatment of alcohol 
dependence, clinicians should maintain awareness of new and 
novel uses of medications for alcohol dependence. Though 
data are inconclusive, there is some suggestion that baclofen 
30–60 mg daily may be safe and effective for the treatment 
of alcohol-dependent individuals with normal renal  function, 
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with or without advanced liver disease, who have not been 
diagnosed with a psychiatric illness and do not carry a his-
tory of seizures.
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